BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26476749)

  • 1. Novel tetracyclic benzo[b]carbazolones as highly potent and orally bioavailable ALK inhibitors: design, synthesis, and structure-activity relationship study.
    Jiang X; Zhou J; Ai J; Song Z; Peng X; Xing L; Xi Y; Guo J; Yao Q; Ding J; Geng M; Zhang A
    Eur J Med Chem; 2015 Nov; 105():39-56. PubMed ID: 26476749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant.
    Sakamoto H; Tsukaguchi T; Hiroshima S; Kodama T; Kobayashi T; Fukami TA; Oikawa N; Tsukuda T; Ishii N; Aoki Y
    Cancer Cell; 2011 May; 19(5):679-90. PubMed ID: 21575866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An orally available tyrosine kinase ALK and RET dual inhibitor bearing the tetracyclic benzo[b]carbazolone core.
    Song Z; Xia Z; Ji Y; Xing L; Gao Y; Ai J; Geng M; Zhang A
    Eur J Med Chem; 2016 Aug; 118():244-9. PubMed ID: 27131066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Brigatinib (AP26113), a Phosphine Oxide-Containing, Potent, Orally Active Inhibitor of Anaplastic Lymphoma Kinase.
    Huang WS; Liu S; Zou D; Thomas M; Wang Y; Zhou T; Romero J; Kohlmann A; Li F; Qi J; Cai L; Dwight TA; Xu Y; Xu R; Dodd R; Toms A; Parillon L; Lu X; Anjum R; Zhang S; Wang F; Keats J; Wardwell SD; Ning Y; Xu Q; Moran LE; Mohemmad QK; Jang HG; Clackson T; Narasimhan NI; Rivera VM; Zhu X; Dalgarno D; Shakespeare WC
    J Med Chem; 2016 May; 59(10):4948-64. PubMed ID: 27144831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
    Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
    Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism-based structure optimization: Discovery of a potent and orally available tyrosine kinase ALK inhibitor bearing the tetracyclic benzo[b]carbazolone core.
    Han M; Wang C; Ji Y; Song Z; Xing L; Su Y; Wang X; Zhang A; Ai J; Geng M
    Bioorg Med Chem Lett; 2016 Nov; 26(22):5399-5402. PubMed ID: 27769623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.
    Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA
    Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).
    Kinoshita K; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Miyagi T; Kobayashi T; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
    Bioorg Med Chem; 2012 Feb; 20(3):1271-80. PubMed ID: 22225917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
    Yoshimura Y; Kurasawa M; Yorozu K; Puig O; Bordogna W; Harada N
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):623-8. PubMed ID: 26849637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 9-substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors.
    Kinoshita K; Kobayashi T; Asoh K; Furuichi N; Ito T; Kawada H; Hara S; Ohwada J; Hattori K; Miyagi T; Hong WS; Park MJ; Takanashi K; Tsukaguchi T; Sakamoto H; Tsukuda T; Oikawa N
    J Med Chem; 2011 Sep; 54(18):6286-94. PubMed ID: 21823617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pyrrole-3-carboxamides as potent and selective JAK2 inhibitors.
    Brasca MG; Nesi M; Avanzi N; Ballinari D; Bandiera T; Bertrand J; Bindi S; Canevari G; Carenzi D; Casero D; Ceriani L; Ciomei M; Cirla A; Colombo M; Cribioli S; Cristiani C; Della Vedova F; Fachin G; Fasolini M; Felder ER; Galvani A; Isacchi A; Mirizzi D; Motto I; Panzeri A; Pesenti E; Vianello P; Gnocchi P; Donati D
    Bioorg Med Chem; 2014 Sep; 22(17):4998-5012. PubMed ID: 25009002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance.
    Kodama T; Tsukaguchi T; Yoshida M; Kondoh O; Sakamoto H
    Cancer Lett; 2014 Sep; 351(2):215-21. PubMed ID: 24887559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.
    Song Z; Yang Y; Liu Z; Peng X; Guo J; Yang X; Wu K; Ai J; Ding J; Geng M; Zhang A
    J Med Chem; 2015 Jan; 58(1):197-211. PubMed ID: 24785465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Alectinib-Based PROTACs as Novel Potent Degraders of Anaplastic Lymphoma Kinase (ALK).
    Xie S; Sun Y; Liu Y; Li X; Li X; Zhong W; Zhan F; Zhu J; Yao H; Yang DH; Chen ZS; Xu J; Xu S
    J Med Chem; 2021 Jul; 64(13):9120-9140. PubMed ID: 34176264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs.
    Geng K; Liu H; Song Z; Zhang C; Zhang M; Yang H; Cao J; Geng M; Shen A; Zhang A
    Eur J Med Chem; 2018 May; 152():76-86. PubMed ID: 29698859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The discovery and optimization of a novel class of potent, selective, and orally bioavailable anaplastic lymphoma kinase (ALK) inhibitors with potential utility for the treatment of cancer.
    Lewis RT; Bode CM; Choquette DM; Potashman M; Romero K; Stellwagen JC; Teffera Y; Moore E; Whittington DA; Chen H; Epstein LF; Emkey R; Andrews PS; Yu VL; Saffran DC; Xu M; Drew A; Merkel P; Szilvassy S; Brake RL
    J Med Chem; 2012 Jul; 55(14):6523-40. PubMed ID: 22734674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrido[2, 3-d]pyrimidin-7(8H)-ones as new selective orally bioavailable Threonine Tyrosine Kinase (TTK) inhibitors.
    Huang M; Huang Y; Guo J; Yu L; Chang Y; Wang X; Luo J; Huang Y; Tu Z; Lu X; Xu Y; Zhang Z; Zhang Z; Ding K
    Eur J Med Chem; 2021 Feb; 211():113023. PubMed ID: 33248853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
    Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor.
    Kang GA; Lee M; Song D; Lee HK; Ahn S; Park CH; Lee CO; Yun CS; Jung H; Kim P; Ha JD; Cho SY; Kim HR; Hwang JY
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3992-8. PubMed ID: 26235945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.